Biogen Inc. (NASDAQ:BIIB) finished Friday with an addition of $4.62 to close at $273.68, an upside of 1.72 percent. An average of 1,019,020 shares of common stock have been traded in the last five days. There was a gain of $4.76 in the past week, and it reached a new high 19 times over the past 12 months. The last 20 days have seen an average of 1,396,405 shares traded, while the 50-day average volume stands at 1,262,938.
BIIB stock has decreased by -1.54% in the last month. The company shares reached their 1-month lowest point of $256.13 on 07/28/23. With the stock rallying to its 52-week high on 06/12/23, shares of the company touched a low of $193.65 and a high of $319.76 in 52 weeks. It has reached a new high 9 times so far this year and lost -1.17% or -$3.24 in price. In spite of this, the price is down -14.41% from the 52-week high.
Insider Transactions
BIIB stock investors should be aware that Biogen Inc. (BIIB) stock had its last reported insider trading activity 40 days ago on Jul 03. In this transaction, the insider spent $22,912. EVP, Human Resources, Gregory Ginger, disposed of 2,681 shares at a price of $300.00 on Apr 28. The insider now owns more than $804,300 worth of shares. Prior to that, Head of Development Singhal Priya went on to Sale 91 shares at $277.11 each on Apr 04. An amount of $25,217 was transacted.
Valuation Metrics
Biogen Inc. (BIIB) has a trailing price-to-earnings (P/E) ratio of 14.91. The stock’s beta is 0.13. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 3.96, the price-to-book (PB) ratio at 2.74, and the price-to-cash flow ratio at 35.13.
Financial Health
The quick ratio of Biogen Inc. for the three months ended June 29 was 2.90, and the current ratio was 3.30, indicating that the company is able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 0.43 and a total debt to equity ratio of 0.00 for the quarter ending June 29. Biogen Inc.’s EBITDA margin for the year ending June 29 is 29.61%, while its operating margin for the same period stands at 31.20%. Its gross profit as reported stood at $7.9 billion compared to revenue of $10.17 billion.
For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Biogen Inc.’s return on assets was 10.70%.
Earnings Surprise
For the three-month period that ended June 29, Biogen Inc. had $3.46 billion in cash and short-term investments compared to $6.28 billion in total debt. In the quarter under review, the net income was down than the previous quarter. The company posted a net income of $591.6 million in the quarter, while revenues of $387.9 million were shrunk -78.84%. The analyst consensus anticipated Biogen Inc.’s latest quarter earnings to come in at $3.77 per share, but it turned out to be $4.02, a 6.60% surprise. For the quarter, EBITDA amounted to $704.3 million. Shareholders own equity worth $144.82 million.
Technical Picture
From a technical analysis perspective, let’s take a brief look at Biogen Inc. (BIIB) price momentum. RSI 9-day as of the close on 11 August was 53.33%, suggesting the stock is Neutral, with historical volatility in this time frame at 16.14%.
As of today, BIIB’s price is $271.88 +1.77% or $4.76 from its 5-day moving average. BIIB is currently trading -1.88% lower than its 20-day SMA and +4.00% higher than its 100-day SMA. However, the stock’s current price level is -8.37% below the SMA50 and +2.27% above the SMA200.
The stochastic %K and %D were 62.64% and 64.06%, respectively, and the average true range (ATR) was 6.46. With the 14-day stochastic at 72.27% and the average true range at 6.41, the RSI (14) stands at 48.49%. The stock has reached 0.57 on the 9-day MACD Oscillator while the 14-day reading was at 2.01.
Analyst Ratings
Scotiabank launched coverage on Biogen Inc. (NASDAQ: BIIB) in its analyst report released on July 27, 2023. The firm assigned the stock a Sector outperform rating.
